Cara Therapeutics News

Buy Rating Affirmed for Cara Therapeutics: Promising Prospects for Oral Difelikefalin in Notalgia Paresthetica Treatment

TipRanksApr 12 06:16 ET

Buy Rating Affirmed for Cara Therapeutics Amidst Promising Korsuva Ph 2/3 Program and Market Potential

TipRanksApr 10 06:35 ET

Cara Therapeutics Analyst Ratings

BenzingaApr 10 06:33 ET

Analysts Are Bullish on These Healthcare Stocks: Celcuity (CELC), Cara Therapeutics (CARA)

TipRanksMar 28 06:00 ET

Cara Therapeutics Analyst Ratings

BenzingaMar 28 05:38 ET

Cara Therapeutics Analyst Ratings

BenzingaMar 6 06:57 ET

Cara Therapeutics Analyst Ratings

BenzingaMar 5 06:29 ET

Cara Therapeutics: Promising Phase 2/3 Trial Progression Fuels Buy Rating

TipRanksMar 5 05:55 ET

Cara Therapeutics Analyst Ratings

BenzingaJan 22 17:06 ET

Strategic Restructuring and Focus on NP Program Justify Buy Rating for Cara Therapeutics

TipRanksJan 22 15:22 ET

HC Wainwright & Co. Maintains Buy on Cara Therapeutics, Lowers Price Target to $2.5

BenzingaDec 19, 2023 06:22 ET

Cara Therapeutics: Resilient Buy Rating Amid Pipeline Setbacks and Future Prospects

TipRanksDec 19, 2023 06:16 ET

Needham Maintains Buy on Cara Therapeutics, Lowers Price Target to $6

BenzingaDec 18, 2023 10:29 ET

Cara Therapeutics Analyst Ratings

BenzingaDec 18, 2023 10:28 ET

Analysts Are Bullish on Top Healthcare Stocks: Viridian Therapeutics (VRDN), Cara Therapeutics (CARA)

TipRanksDec 18, 2023 10:10 ET

Analysts Offer Insights on Healthcare Companies: CureVac (CVAC), MoonLake Immunotherapeutics (MLTX) and Cara Therapeutics (CARA)

TipRanksNov 14, 2023 12:50 ET

Piper Sandler Downgrades Cara Therapeutics to Neutral, Lowers Price Target to $1

BenzingaNov 14, 2023 05:59 ET

Cara Therapeutics Analyst Ratings

BenzingaNov 14, 2023 05:57 ET

HC Wainwright & Co. Maintains Buy on Cara Therapeutics, Lowers Price Target to $7

BenzingaOct 19, 2023 06:49 ET

Cara Therapeutics Analyst Ratings

BenzingaOct 19, 2023 06:48 ET